WAVE Life Sciences Ltd
NASDAQ:WVE
WAVE Life Sciences Ltd
Revenue
WAVE Life Sciences Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Revenue
$108.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Revenue
S$244.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Revenue
S$195.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Revenue
S$7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
WAVE Life Sciences Ltd
Glance View
WAVE Life Sciences Ltd. is a biotechnology company that sprawls across the intricate landscape of genetic medicine, focusing tirelessly on harnessing the therapeutic potential of stereochemistry in designing drugs. Founded with an innovative spirit, the company has carved out a niche by developing stereopure oligonucleotides, which are synthetically crafted RNA or DNA molecules tailored to enhance therapeutic efficacy and safety. The precision and clarity with which WAVE defines each aspect of its drug candidates separate them from many competitors in the gene therapy arena. With their proprietary platform, PRISM, WAVE leverages a deep understanding of genetic and molecular nuances to address rare genetic diseases. Their pipeline is reflective of this targeted approach, with clinical trials and research focusing on conditions like Huntington's disease, Duchenne Muscular Dystrophy, and other inherited disorders that have limited treatment options. The business model of WAVE revolves around both in-house development and strategic partnerships, driving revenue through research collaborations and potential milestone payments. By collaborating with larger pharmaceutical entities, WAVE amplifies its reach and resources, allowing it to tackle more complex challenges in genetic diseases. These partnerships are financially synergistic, enabling WAVE to continuously invest in its R&D efforts, which are pivotal for long-term growth and sustainability. The company’s focus on innovative medicines and the establishment of credible partnerships underscores its dual strategy of creating breakthrough treatments while maintaining a robust financial backbone, striving to transform the landscape of genetic therapies ethically and effectively.
See Also
What is WAVE Life Sciences Ltd's Revenue?
Revenue
108.3m
USD
Based on the financial report for Dec 31, 2024, WAVE Life Sciences Ltd's Revenue amounts to 108.3m USD.
What is WAVE Life Sciences Ltd's Revenue growth rate?
Revenue CAGR 5Y
47%
Over the last year, the Revenue growth was -4%. The average annual Revenue growth rates for WAVE Life Sciences Ltd have been 38% over the past three years , 47% over the past five years .
You don't have any saved screeners yet